Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial

Main Article Content

Amy Paller
Northwestern University Feinberg School of Medicine

Andrew Blauvelt
Oregon Medical Research Center, Portland, OR, USA

Weily Soong
Allervie Health-Alabama Allergy & Asthma Center

Shinichi Imafuku
Fukuoka University Hospital, Fukuoka, Japan

Chih-ho Hong
University of British Columbia

Marie Schuttelaar
University Medical Centre Groningen

Petra Amoudruz
LEO Pharma A/S, Ballerup, Denmark

Azra Kurbasic
LEO Pharma A/S, Ballerup, Denmark

Lise Soldbro
LEO Pharma A/S, Ballerup, Denmark

Katja Lophaven
LEO Pharma A/S, Ballerup, Denmark

Michael Cork
University of Sheffield

Anthony Bewley
Barts Health NHS Trust

Eric Simpson
Oregon Medical Research Center, Portland, OR, USA

Keywords

atopic dermatitis

Abstract

N/A

References

1. Marciniak J. Acta Derm Venereol. 2017;97(6):711–714. doi: 10.2340/00015555-2633.

2. Ricci G. Dermatol Reports.
2011;4(1):e1. doi: 10.4081/dr.2012.e1.

3. Slattery M. J Allergy Clin Immunol. 2011; 128(3):668–671.e3. doi:
10.1016/j.jaci.2011.05.003.

4. Halvorsen J. J Invest Dermatol. 2014;134(7):1847–1854. doi: 10.1038/jid.2014.70.

5. Bieber T.
Allergy. 2020;75(1):54-62. doi: 10.1111/all.13954.

6. Furue K et al. Immunology. 2019; 158(4): 281-286. doi: 10.1111/imm.13120.


7. Szegedi K et al. JEADV. 2015;29(11):2136–2144. doi: 10.1111/jdv.13160.

8. Tsoi LC et al. J Invest Dermatol.
2019;139(7):1480-1489. doi: 10.1016/j.jid.2018.12.018.

9. Popovic B et al. J Mol Biol. 2017; 429(2): 208–219. doi:

10.1016/j.jmb.2016.12.005. 10. Wollenberg A. Br J Dermatol. 2021; 184(3):437–449. doi: 10.1111/bjd.19574.

Article Sidebar

Poster PDF
Published
Mar 4, 2022
DOI https://doi.org/10.25251/skin.6.supp.s29

Article Details

How to Cite
[1]
Paller, A. , Blauvelt, A. , Soong, W., Imafuku, S., Hong, C.- ho, Schuttelaar, M. , Amoudruz, P., Kurbasic, A., Soldbro, L., Lophaven, K., Cork, M., Bewley, A. and Simpson, E. 2022. Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial. SKIN The Journal of Cutaneous Medicine. 6, 2 (Mar. 2022), s29. DOI:https://doi.org/10.25251/skin.6.supp.s29.
Issue
Vol. 6 No. 2 (2022): March Issue and Poster Presentations (FC PANP 21 and WC 22 Dermatology Conferences®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>